Medicenna Therapeutics Corp.
MDNAF
$0.7151
-$0.0289-3.88%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.69% | -23.09% | -25.02% | 192.64% | -9.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.17% | -0.03% | -11.05% | 73.09% | -3.15% |
| Operating Income | -4.17% | 0.03% | 11.05% | -73.09% | 3.15% |
| Income Before Tax | -1.37% | -9.99% | -24.75% | -261.74% | -335.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.37% | -9.99% | -24.75% | -261.74% | -335.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.37% | -9.99% | -24.75% | -261.74% | -335.19% |
| EBIT | -4.17% | 0.03% | 11.05% | -73.09% | 3.15% |
| EBITDA | -4.13% | 0.12% | 11.14% | -73.12% | 3.15% |
| EPS Basic | 9.52% | 0.50% | -17.97% | -261.22% | -333.88% |
| Normalized Basic EPS | 9.45% | 0.40% | -18.32% | -261.72% | -337.33% |
| EPS Diluted | 9.52% | 0.50% | -17.97% | -261.22% | -333.88% |
| Normalized Diluted EPS | 9.45% | 0.40% | -18.32% | -261.72% | -337.33% |
| Average Basic Shares Outstanding | 12.02% | 10.34% | 5.72% | 0.13% | 0.00% |
| Average Diluted Shares Outstanding | 12.02% | 10.34% | 5.72% | 0.13% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
